Atrium Therapeutics, Inc.

-- ATR 1072 impacted key characteristics of PRKAG2 syndrome, including accumulation ofcardiac glycogen and cardiac hypertrophy -- -- Data further reinforce scientific rationale for ATR 1072 targeting the root cause ofPRKAG2 syndrome -- -- Poster presentation November 6 at 5:30 p.m. CT -- SAN DIEGO, Nov. 2, 2026 /PRNewswire/ -- Atrium Therapeutics, Inc. (Nasdaq: RNA) (the "Company"), a biopharmaceutical company advancing precision cardiology by developing RNA therapeutics targeted to the heart, t…

-- Global Phase 1/2 trial will evaluate ATR 1072 in approximately 37 participants -- -- Initial proof of concept data expected in second half of 2027 -- SAN DIEGO, Oct. 27, 2026 /PRNewswire/ -- Atrium Therapeutics, Inc. (Nasdaq: RNA) (the "Company"), a biopharmaceutical company advancing precision cardiology by developing RNA therapeutics targeted to the heart, today announced that the first patient has been dosed in the Phase 1/2 Corventis clinical trial evaluating ATR 1072, its lead investigat…

SAN DIEGO, Oct. 20, 2026 /PRNewswire/ -- Atrium Therapeutics, Inc. (Nasdaq: RNA) (the "Company") today announced it awarded inducement grants on October 20, 2026 under the Company's 2026 Employment Inducement Incentive Award Plan (the "2026 Inducement Plan") as a material inducement to the employment of one non-executive individual newly hired by the Company. The employee received, in the aggregate, non-qualified stock options to purchase 9,500 shares of the Company's common stock, par value $0.…

Yakira urges Board to explore strategic alternatives before further cash burn and dilution erode shareholder value; questions decision to raise $50 million after shares fell approximately 44% at a valuation near fifty percent of net cash WESTPORT, Conn., Oct. 20, 2026 /PRNewswire/ -- Yakira Capital Management, Inc. ("Yakira") a shareholder of Atrium Therapeutics, Inc. (NASDAQ: RNA), today called on the Company's Board of Directors to immediately initiate a strategic review, curtail cash spending…

What happened Atrium Therapeutics, Inc. (NASDAQ: RNA) said on October 7, 2026, that it entered a securities purchase agreement. The company said the financing is expected to bring in about $50 million in gross proceeds before placement agent fees and other offering expenses. The agreement covers 5,170,384 shares of common stock at $7.93 a share

SAN DIEGO, Oct. 8, 2026 /PRNewswire/ -- Atrium Therapeutics, Inc. (Nasdaq: RNA) ("Atrium" or the "Company"), a biopharmaceutical company advancing precision cardiology by developing RNA therapeutics targeted to the heart, today announced that it has entered into a securities purchase agreement (the "purchase agreement") with a group of leading institutional investors for a private placement financing (the "private placement"). The private placement is expected to result in aggregate gross procee…

Shares of Avidity Biosciences, Inc. (NASDAQ: RNA - Get Free Report) crossed below its 200-day moving average during trading on Tuesday. The stock has a 200-day moving average of $12.37 and traded as low as $7.78. Avidity Biosciences shares last traded at $7.99, with a volume of 411,683 shares traded. Analysts Set New Price Targets RNA

SAN DIEGO, Sept. 21, 2026 /PRNewswire/ -- Atrium Therapeutics, Inc. (Nasdaq: RNA) (the "Company") today announced it awarded inducement grants on September 20, 2026 under the Company's 2026 Employment Inducement Incentive Award Plan (the "2026 Inducement Plan") as a material inducement to the employment of one non-executive individual newly hired by the Company.

Avidity Biosciences, Inc. (NASDAQ: RNA - Get Free Report)'s share price crossed below its 200-day moving average during trading on Wednesday. The stock has a 200-day moving average of $15.18 and traded as low as $10.34. Avidity Biosciences shares last traded at $10.51, with a volume of 690,299 shares changing hands. Analyst Upgrades and Downgrades

SAN DIEGO, Sept. 2, 2026 /PRNewswire/ -- Atrium Therapeutics, Inc. (Nasdaq: RNA), a biopharmaceutical company advancing precision cardiology by developing RNA therapeutics targeted to the heart, today announced that it will participate in upcoming investor conferences in September.

SAN DIEGO, Aug. 20, 2026 /PRNewswire/ -- Atrium Therapeutics, Inc. (Nasdaq: RNA) (the "Company") today announced it awarded inducement grants on August 20, 2026 under the Company's 2026 Employment Inducement Incentive Award Plan (the "2026 Inducement Plan") as a material inducement to the employment of one non-executive individual newly hired by the Company. The employee received, in the aggregate, non-qualified stock options to purchase 11,000 shares of the Company's common stock, par value $0.…

-- IND clearance for ATR 1072 and launch of Corventis Phase 1/2 trial in PRKAG2 syndrome -- -- Achieved second milestone payment under global cardiovascular collaboration with Bristol Myers Squibb -- SAN DIEGO, Aug. 13, 2026 /PRNewswire/ -- Atrium Therapeutics, Inc. (Nasdaq: RNA) ("Atrium," "Atrium Therapeutics," or the "Company"), a biopharmaceutical company advancing precision cardiology by developing RNA therapeutics targeted to the heart, today reported financial results for the second quart…

SAN DIEGO, Aug. 13, 2026 /PRNewswire/ -- Atrium Therapeutics, Inc. (Nasdaq: RNA) ("Atrium," "Atrium Therapeutics" or the "Company"), a biopharmaceutical company dedicated to delivering RNA therapeutics to the heart, today announced it has earned another $15 million milestone payment from Bristol Myers Squibb (NYSE: BMY) based on the successful delivery of a lead compound targeting an undisclosed cardiology indication under the Company's ongoing collaboration. "Atrium's vision is to deliver treat…